Latest News about NVS
Recent news which mentions NVS
3 Health Care Stocks Whale Activity In Today's Session
April 08, 2025
From Benzinga
From Benzinga
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
April 01, 2025
From Benzinga
From Benzinga
From Benzinga
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
March 21, 2025
From Benzinga
From Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
March 19, 2025
From Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
March 18, 2025
From Motley Fool
From Motley Fool
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
March 06, 2025
From Benzinga
From Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
March 01, 2025
From Motley Fool
From Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
February 24, 2025
From Benzinga
From Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
February 11, 2025
From Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
February 10, 2025
From Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
February 07, 2025
From Benzinga
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
February 03, 2025
From Motley Fool
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
January 31, 2025
From Benzinga
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
January 31, 2025
From Benzinga
Earnings Scheduled For January 31, 2025
January 31, 2025
From Benzinga
From Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
From Benzinga
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.